GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDING CO., LTD.

Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd.

874 CNE100000387

Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd. specializes in researching, developing and manufacturing pharmaceutical products. The group's products include analgesics, antibiotics, medicines for the treatment of stomach disorders, treatment of cough, antitoxic products, etc.

Sector

Pharmaceuticals

Calendar

16/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

19.35 CNY

Average target price

23.96 CNY

Spread / Average Target

+23.80%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDING CO., LTD.	-5.29%	6.31B
ELI LILLY AND COMPANY	+54.61%	811B
NOVO NORDISK A/S	+43.53%	640B
JOHNSON & JOHNSON	-6.33%	353B
MERCK & CO., INC.	+20.62%	333B
ABBVIE INC.	+10.44%	302B
ASTRAZENECA PLC	+17.79%	246B
ROCHE HOLDING AG	+2.37%	225B
NOVARTIS AG	+12.56%	218B
AMGEN INC.	+8.61%	168B

Other Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 01:38:08 27/06/2024 pm IST			5-day change	1st Jan Change
20.6 ^HKD	-0.96%		-4.19%	-5.29%

07:22am	Guangzhou Baiyunshan Pharmaceutical Secures Drug Registration for Erectile Dysfunction Tablets	MT
19/06	Baiyunshan Pharmaceutical's Unit Gets Regulatory Nod to Add Specification for Dopamine Hydrochloride Injection	MT

Guangzhou Baiyunshan Pharmaceutical Secures Drug Registration for Erectile Dysfunction Tablets	10:52am	MT
Baiyunshan Pharmaceutical's Unit Gets Regulatory Nod to Add Specification for Dopamine Hydrochloride Injection	19/06	MT
Baiyunshan Pharmaceutical's Unit Gets Nod from Macao's Drug Regulator to Import, Export Pearl Powder	17/06	MT
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04	CI
Baiyunshan Pharmaceutical's 2023 Profit Rises 2%	18/03	MT
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Proposes Final Ordinary Dividend for the Year Ended 31 December 2023, Payable on 18 July 2024	15/03	CI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
Baiyunshan Pharma's Unit Gets Green Light to Produce Hepatitis B Drug	01/03	MT
Guangzhou Pharma Unit Gets Green Light to Trial Oral Liquid Drug	09/02	MT
Guangzhou Baiyunshan Pharmaceutical Arm Floats 1 Billion Yuan Biomedical VC Fund	19/12	MT
Guangzhou Baiyunshan Pharmaceutical Ends Spin-Off Plans, Seeks China Listing for Subsidiary	19/12	MT
Guangzhou Pharma Expands Scope of Drug Production License	13/11	MT
Guangzhou Baiyunshan Pharmaceutical's Profit Up 11% in Q3	30/23/30	MT
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30	CI
Baiyunshan Pharmaceutical Reports Increase in H1 Attributable Profit	13/23/13	MT
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023	17/23/17	CI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(SHSE:600332) added to Shanghai Stock Exchange 180 Value Index	12/23/12	CI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(SHSE:600332) added to SSE 180 Index	12/23/12	CI
Guangzhou Pharma Registers Pain-Relief, Anti-Inflammatory Drugs in Russia	26/23/26	MT
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the First Quarter Ended March 30, 2023	27/23/27	CI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Announces Election of the Supervisor Representing the Employees of the 9th Session of the Supervisory Committee	25/23/25	CI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Announces Final Dividend for the Year Ended 31 December 2022	17/23/17	CI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022	17/23/17	CI
Baiyunshan Pharma to Inject 334 Million Yuan Into New Fund	02/23/02	MT
Baiyunshan Pharma Gets Nod for Tablets for Male Patients	09/23/09	MT

Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd.

Equities

874

CNE100000387